GlassScriptPhysician profile
Alan K Matsumoto
NPI 1043219298
$184,789.07
in general payments reported to CMS, 2019-2025
30 companies · $18K in 2025
The $18K reported for 2025 was more than what 92% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52K · 2020: $16K · 2021: $9,858 · 2022: $22K · 2023: $40K · 2024: $28K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $22K · Honoraria: $22K · Consulting Fee: $21K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $4,345 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $21,864.93 |
| Honoraria | $21,761.15 |
| Consulting Fee | $21,391.45 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,829.23 |
| Food and Beverage | $4,344.95 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $46,986.16 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $27,669.25 | 2019-2025 | |
| Abbvie INC. | $27,136.77 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $25,763.74 | 2022-2025 | Tremfya |
| Gilead Sciences, INC. | $22,420.65 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $13,305.18 | 2019-2023 | |
| Gw Pharma Limited | $5,850.00 | 2019 | |
| Lilly USA, LLC | $4,192.42 | 2019-2020 | |
| Genzyme Corporation | $4,078.85 | 2019 | |
| Amgen INC. | $2,157.80 | 2019-2025 | Tavneos, Krystexxa |
| Genentech USA, INC. | $1,577.31 | 2019-2024 | Actemra |
| Genentech, INC. | $1,148.54 | 2025 | |
| Glaxosmithkline, LLC. | $1,056.65 | 2019-2022 | |
| Assertio Therapeutics, INC. | $475.43 | 2022 | |
| Ucb, INC. | $200.37 | 2019-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $161.64 | 2019-2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $145.17 | 2021-2022 | |
| Sobi, INC | $124.40 | 2023 | |
| Aurinia Pharma U.S., INC. | $113.40 | 2023 | |
| Radius Health, INC. | $57.99 | 2019 | |
| Pacira Therapeutics, INC. | $48.94 | 2019 | |
| Merck Sharp & Dohme LLC | $35.86 | 2019 | |
| Zimmer Biomet Holdings, INC. | $29.14 | 2019 | |
| Celgene Corporation | $21.86 | 2019 | |
| Horizon Therapeutics Plc | $16.98 | 2020 | |
| Depuy Synthes Sales INC. | $14.57 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Matsumoto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.